A long battle to find an effective solution for adhesions from abdominal surgery could finally be over thanks to a new treatment that originated at the University of Saskatchewan.

Adhesions, or rope-like scar tissues, form in roughly 80 per cent of patients who undergo abdominal surgery. One-third of people who have them also deal with severe pain. Advancing technology out of USask has allowed researchers to develop a clinically tested pharmaceutical solution to this problem. In a recent human trial, the treatment, known as TTX333, showed a 93 per cent success rate in preventing adhesions after the removal of uterine fibroids. These findings have the potential to dramatically change the lives of women post-surgery, as cesarian sections have been known to cause the adhesions. The findings were published in the European Journal of Obstetrics and Gynecology and Reproductive Biology.